A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia
Status:
Completed
Trial end date:
2018-02-14
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once
daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having
achieved normokalemia following two days of initial ZS therapy (10g TID).